[Therapeutic effect of hysteroscopic surgery in treatment of small mass of caesarean scar pregnancy].
OBJECTIVE
Study the effect of hysteroscopic surgery in treatment of small mass of caesarean scar pregnancy (CSP).


METHODS
From January 2000 to January 2013, 61 cases lesions ≤ 2.5 cm diameter of endogenous CSP undergoing treatment in Luohe Central Hospital were studied retrospectively. According to different treatment, they were divided into 21 cases in hysteroscopic surgery group, 23 cases in methotrexate+operation group and 17 cases in bilateral uterine artery embolism+curettage group.Intraoperative blood loss, operative time, hospitalization time after treatment and β-hCG to normal time were compared among those three groups.


RESULTS
The surgical blood loss, hospitalization time after treatment, β-hCG to normal time were (49.8 ± 6.2) ml, (3.5 ± 0.8) days, (21.2 ± 2.4) days in hysteroscopic group, (87.0 ± 30.5) ml, (12.5 ± 1.0) days, (29.6 ± 2.2) days in methotrexate+operation group, the difference was statistically significant (P < 0.05). The operation time were (33 ± 4) minutes in hysteroscopic surgery group and (35 ± 6) minutes in methotrexate+operation group, which did not reached significant difference (P > 0.05). Length of hospital stay after treatment of hysteroscopic surgery group is less than the bilateral uterine artery embolism+curettage group significantly (P < 0.05).Operation time, surgical bleeding and β-hCG to normal time had no obvious difference between hysteroscopic surgery and in bilateral uterine artery embolism+curettage group (P > 0.05).


CONCLUSIONS
Hysteroscopy surgery in treatment of small mass endogenous CSP is effective, shorter hospitalization time, quick recovery.
Department of Obstetrics and Gynecology, Luohe Central Hospital, Luohe 462000, China. Email: lvjingshang@163.com.
Jingshang
J
Lyu
Department of Obstetrics and Gynecology, Luohe Central Hospital, Luohe 462000, China.
Xiuhong
X
Fu
Department of Obstetrics and Gynecology, Luohe Central Hospital, Luohe 462000, China.
Huifen
H
Wang
D000328:Adult; D002585:Cesarean Section / Q000009:adverse effects*; D018997:Chorionic Gonadotropin, beta Subunit, Human / Q000097:blood; D002921:Cicatrix / Q000150:complications*; D003475:Curettage; D005260:Female; D006801:Humans; D015907:Hysteroscopy / Q000379:methods*; D008727:Methotrexate / Q000008:administration & dosage / Q000627:therapeutic use; D011183:Postoperative Complications / Q000453:epidemiology / Q000628:therapy; D011247:Pregnancy; D011271:Pregnancy, Ectopic / Q000188:drug therapy / Q000209:etiology / Q000601:surgery*; D012189:Retrospective Studies; D016896:Treatment Outcome; D055357:Uterine Artery Embolization; D014599:Uterus / Q000098:blood supply / Q000601:surgery
D018997:Chorionic Gonadotropin, beta Subunit, Human; D008727:Methotrexate